Clinical trial NCT04590261: Myeloid Cells in Patients With Covid-19 Pneumonia
Official title: Myeloid Cells in Patients With Covid-19 Pneumonia
Study type: INTERVENTIONAL
Overall status: NOT_YET_RECRUITING
Phase: NA
Conditions: Covid-19; SARS-Cov2
Keywords: Covid-19
Neutrophils
Dendritic cells
Monocytes
Macrophages
Interferons
Nasal mucosa
Peripheral blood
Pneumonia
Lead sponsor: Assistance Publique - Hôpitaux de Paris
Sponsor class: OTHER
Collaborators: name: Institut National de la Santé Et de la Recherche Médicale, France
First posted: 2020-10-19
Enrollment: 120
Sex: ALL
Minimum age (years): 18
Maximum age (years): 70
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Allocation: NON_RANDOMIZED
Intervention model: PARALLEL
Primary purpose: SCREENING

Brief summary: The purpose of this study is to analyze in depth the relationship of myeloid cell subpopulations during infection by Severe acute respiratory syndrome coronavirus 2 (SARS-Cov2), the virus mediating Covid-19. Myeloid cells include neutrophils, monocytes and dendritic cells, each divided into subpopulations with different functions in immune defense and immune pathologies.

The study is based on the following hypotheses:

* Infection and the interferon response to infection may induce hyperactive or immunosuppressive differentiation of myeloid cells, that may be treated by specific inhibitors.
* Some myeloid cell subpopulations currently identified in our laboratories might be markers for Covid-19 prognosis.
* Alternative receptors may be present on myeloid cells, inducing the cytokine storm, a target for therapy.
* The expression of Interferon (IFN) receptor and IFN responding genes on myeloid cells and on respiratory epithelial cells may correlate with prognosis and indicate potential treatment targets.
* Interferon responses are known to be skewed during Covid-19, but some IFN subtype polymorphisms may correlate with prognosis and these subtypes migt be supplemented or inhibited for therapy.

Detailed description: Infection by SARS-Cov2 drives to pneumonia in most cases, 30 percent of which require hospitalization in a pneumology ward, among which 30 percent with severe acute respiratory syndrome (SARS) must go to critical care units, with a high mortality rate.

This infection drives a strong cytokine response. In patients developing SARS, a profound, paradoxical defect in IFN alpha and in the expression of genes responding to IFN alpha was discovered. IFNs are strong anti-viral proteins, used for the treatment of viral hepatitis. Type I IFNs, including IFN alpha, have ubiquitous receptors on almost every cell type. Type III IFNs, or IFN lambda, have a more restricted receptor expression, including on neutrophils. Their polymorphisms were already related to the prognosis of another ribonucleic acid (RNA) virus with mucosal entry, hepatitis C virus (HCV), especially in people with African origins.

Coronaviruses responsible for the previous SARS-Cov or Middle East respiratory syndrome coronavirus (MERS-Cov) epidemics induce a defective IFN signal transduction. Many other viral infection lead to desensitization. Moreover, IFN alpha by itself can lead to defective antiviral responses. At the immune cell level, lymphopenia with an increased neutrophil/lymphocyte ratio were noted in severe SARS-Cov2 case. New subpopulations of neutrophils have been characterized by phenotypic and proteomic studies, with inflammatory or suppressive functions.

It will be important to know if

* hyperactive or immunosuppressive myeloid cell differentiation is caused by SARS-Cov2 and can be inhibited specifically.
* some myeloid subpopulations
* correlate with the prognosis of the disease,
* myeloid cells have alternative receptors for SARS-Cov2,
* some IFN polymorphisms may correlate with prognosis and might be supplemented or inhibited for therapy.

The answers will be obtained through the primary and secondary outcome measures, as described below.

Eligibility criteria: Inclusion Criteria:

* Age \> 18 years
* Sex : male or female
* French Social Security insurance
* Information and consent dated and signed \*
* Group 1 : inclusion 2 to 12 months after hospitalization for Covid-19 pneumonia with mild severity (oxygen treatment ≤5L/mn);
* Group 2 : 2 to 12 months after hospitalization for Covid-19 pneumonia with high severity (oxygen treatment \>5L/mn);
* Group 3 : external visit at Cochin Hospital, age- and sex -matched with Groups 1, 2, 4.
* Group 4 : inclusion during hospitalization for Covid-19, within the first month of symptoms.

Exclusion Criteria:

* Tuberculosis or other evolutive bacterial infection
* Chronic evolutive viral Infections (Hepatitis B or C, HIV)
* Ongoing chemotherapy or radiotherapy
* Participation in another research protocol with current exclusion period at the time of pre-inclusion (possible inclusion in an observational study
* Vulnerable person (pregnant, parturient woman, breastfeeding woman, person Under tutorship, person under arrest through judiciary or administrative decision )

Primary outcomes:
measure: Myeloid cell sub-population phenotype
timeFrame: Month zero-month 36
Secondary outcomes:
measure: Myeloid cell functions
timeFrame: Month zero-month 36
measure: Myeloid cell transcriptomic and proteomic study
timeFrame: Month zero-month 36
measure: Transcriptomic study of nasal epithelial cells
timeFrame: Month zero-month 36
measure: Plasma analyte concentration measurement
timeFrame: Month zero-month 36
Other outcomes:
Locations:
Study officials:
affiliation: Cochin Hospital
name: Pierre-Régis Burgel, MD, PhD
role: PRINCIPAL_INVESTIGATOR
References: